Merck & Company (MRK) stock had a bullish inflow of $42.97 million worth of trades on uptick and an outflow of $33.09 million in downticks on Friday. The total uptick to downtick ratio stood at 1.3. The net money flow into the stock was $9.88 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $9.01 million. $9.01 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Merck & Company (MRK) stock traded down $0.01 , and reached $58.78, a drop of -0.02% over the previous day. On a weekly basis, the stock is -1.43%, over the previous weeks close.
Merck & Company (MRK) : The consensus price target for Merck & Company (MRK) is $62.33 for the short term with a standard deviation of $7.66. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $80, however, the pessimist price target for the company is $53.
Merck & Company (NYSE:MRK): stock turned positive on Friday. Though the stock opened at $58.99, the bulls momentum made the stock top out at $59.08 level for the day. The stock recorded a low of $58.55 and closed the trading day at $58.82, in the green by 0.05%. The total traded volume for the day was 6,269,481. The stock had closed at $58.79 in the previous days trading.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Exe V-P, HR) of Merck & Co., Inc., Graddick Weir Mirian M had sold 45,000 shares worth of $2,608,200 in a transaction dated July 5, 2016. In this transaction, 45,000 shares were sold at $57.96 per share.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.